1. Home
  2. CCO vs ANAB Comparison

CCO vs ANAB Comparison

Compare CCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clear Channel Outdoor Holdings Inc.

CCO

Clear Channel Outdoor Holdings Inc.

HOLD

Current Price

$2.41

Market Cap

1.2B

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$62.39

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCO
ANAB
Founded
1995
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
CCO
ANAB
Price
$2.41
$62.39
Analyst Decision
Hold
Buy
Analyst Count
5
12
Target Price
$2.12
$71.67
AVG Volume (30 Days)
9.0M
570.6K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
110.81
91.02
EPS
N/A
N/A
Revenue
$1,604,140,000.00
$234,603,000.00
Revenue This Year
$5.35
N/A
Revenue Next Year
$4.26
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
6.57
157.01
52 Week Low
$1.00
$17.11
52 Week High
$2.43
$73.30

Technical Indicators

Market Signals
Indicator
CCO
ANAB
Relative Strength Index (RSI) 51.08 56.57
Support Level $2.37 $52.32
Resistance Level $2.41 $67.69
Average True Range (ATR) 0.02 3.27
MACD 0.00 0.87
Stochastic Oscillator 50.00 54.78

Price Performance

Historical Comparison
CCO
ANAB

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: